Eurobio Scientific SA (ALERS) - Total Liabilities
Based on the latest financial reports, Eurobio Scientific SA (ALERS) has total liabilities worth €78.26 Million EUR (≈ $91.49 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALERS cash flow conversion to assess how effectively this company generates cash.
Eurobio Scientific SA - Total Liabilities Trend (2007–2024)
This chart illustrates how Eurobio Scientific SA's total liabilities have evolved over time, based on quarterly financial data. Check ALERS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Eurobio Scientific SA Competitors by Total Liabilities
The table below lists competitors of Eurobio Scientific SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Praemium Ltd
AU:PPS
|
Australia | AU$19.53 Million |
|
Bank Yudha Bhakti Tbk
JK:BBYB
|
Indonesia | Rp14.07 Trillion |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
Korea | ₩40.00 Billion |
|
Honghua Group Limited
F:4HB
|
Germany | €9.06 Billion |
|
Activate Energy Acquisition Corp. Class A Ordinary Share
NASDAQ:AEAQ
|
USA | $147.51K |
|
First National Corp
NASDAQ:FXNC
|
USA | $1.85 Billion |
|
Hyundai Cement
KO:006390
|
Korea | ₩469.22 Billion |
|
Secuoya Grupo de Comunicación S.A
MC:SEC
|
Spain | €121.29 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Eurobio Scientific SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Eurobio Scientific SA market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.74 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eurobio Scientific SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eurobio Scientific SA (2007–2024)
The table below shows the annual total liabilities of Eurobio Scientific SA from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €78.31 Million ≈ $91.56 Million |
-44.52% |
| 2023-12-31 | €141.16 Million ≈ $165.03 Million |
-10.52% |
| 2022-12-31 | €157.75 Million ≈ $184.42 Million |
+221.93% |
| 2021-12-31 | €49.00 Million ≈ $57.29 Million |
-23.97% |
| 2020-12-31 | €64.45 Million ≈ $75.35 Million |
+45.03% |
| 2019-12-31 | €44.44 Million ≈ $51.96 Million |
+10.35% |
| 2018-12-31 | €40.27 Million ≈ $47.09 Million |
+0.99% |
| 2017-12-31 | €39.88 Million ≈ $46.62 Million |
+102.84% |
| 2016-12-31 | €19.66 Million ≈ $22.99 Million |
+58.52% |
| 2015-12-31 | €12.40 Million ≈ $14.50 Million |
-1.16% |
| 2014-12-31 | €12.55 Million ≈ $14.67 Million |
-2.34% |
| 2013-12-31 | €12.85 Million ≈ $15.02 Million |
-8.17% |
| 2012-12-31 | €13.99 Million ≈ $16.36 Million |
+246.70% |
| 2011-12-31 | €4.04 Million ≈ $4.72 Million |
-66.56% |
| 2010-12-31 | €12.07 Million ≈ $14.11 Million |
+8.83% |
| 2009-12-31 | €11.09 Million ≈ $12.97 Million |
-44.84% |
| 2008-12-31 | €20.11 Million ≈ $23.51 Million |
+3.00% |
| 2007-12-31 | €19.52 Million ≈ $22.82 Million |
-- |
About Eurobio Scientific SA
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monito… Read more